<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>29012</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_pmc">29012</infon><infon key="article-id_pmid">11056722</infon><infon key="article-id_publisher-id">cc-3-1-039</infon><infon key="fpage">39</infon><infon key="issue">1</infon><infon key="journal-title">Critical Care</infon><infon key="kwd">cisapride mechanical ventilation aspiration pneumonia VAP</infon><infon key="lpage">43</infon><infon key="name_0">surname:Pneumatikos;given-names:John</infon><infon key="name_1">surname:Koulouras;given-names:Basil</infon><infon key="name_2">surname:Frangides;given-names:Christ</infon><infon key="name_3">surname:Goe;given-names:Dian</infon><infon key="name_4">surname:Nakos;given-names:George</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">3</infon><infon key="year">1999</infon><offset>0</offset><text>Cisapride decreases gastric content aspiration in mechanically 		  ventilated patients</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>87</offset><text>Purpose:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>98</offset><text>To ascertain the impact of cisapride, a prokinetic agent, on the inhibition of gastric contents.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>213</offset><text>Redesigning:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>221</offset><text>A two-stage crossover study that involved randomized controls and participants.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>274</offset><text>The environment in question:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>283</offset><text>A polyvalent intensive care unit with fourteen beds is located in a University Hospital.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>357</offset><text>Patients:.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>367</offset><text>The study involved 18 patients who were semirecumbent, intubated, and mechanically ventilated.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>482</offset><text>The strategy:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>490</offset><text>Tc-99 m sulfur colloid (80 megabecquerels) was given via nasogastric tube on 2 days. Patients were randomly given cisapride (10 mg, via the gynecological tube) one day and placebo the other. Bronchial secretions were obtained before and for 5 consecutive h after Tactical Medicinal Investigation. The radioactivity measured in a standard amount (1ml) of bronchiAL fluid using taq comparator.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>979</offset><text>What are the results?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>988</offset><text>The radioactivity of the bronchial secretions was increased in 16 out of 18 patients (88%), with an increase with and without cisapride, although it was not as high as in those receiving a placebo. The cumulative occurrence of pulmonary euphoria (PR) radioactively was significantly lower than when subjects received CIsaPride (7540  5330 and 21965 &#1076;&#1086;&#1083; 16080 CPm) when compared to placebo controls (P 0.05) (76.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1473</offset><text>The conclusion can be reached by retracing the steps.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1485</offset><text>We found that even in patients kept in a semirecumbent position, aspiration of gastric contents still occurs and this finding was correct. Cisapride reduced the amount of airway gastritis associated with ventilator-associated pneumonia in intubated and mechanically ventilated patients, but it did not prevent complete gastrinary aspartam inciprance (even when the patient was in the semirest position).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1946</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1959</offset><text>An introduction to cisapride

Cisapride is a new class of drugs that is being developed to treat gastric ulceration. The reason for the development of cisapride is that it is an effective and safe treatment for irenal ulceration which is commonly seen in patients with ulcerative colitis (UC). In the early stages of UC, the ulceration is usually not present and there is no ulceration. However, as the ulceration progresses, patients become increasingly irritable, and have difficulty swallowing. The ulceration is usually caused by the abnormal removal of the colonic mucosa by the irenal ulceration. The ulceration is usually caused by the removal of the colonic mucosa by the irenal ulceration.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2193</offset><text>Aspiration of gastric contents is more common in ICU patients and higher in intubated and mechanically ventilated patients, with gastroesophageal tract dysmotility being a contributing factor to the high incidence of aspirations.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3992</offset><text>Cisapride is a potent prokinetic medication that enhances the release of acetylcholine from the postganglionic nerve endings of the myenteric plexus without any dopamine antagonism.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4220</offset><text>The effectiveness of cisapride in preventing gastric contents from aspirating through the lungs in patients on mechanical ventilators while still maintaining their semi-recumbent position was evaluated in this study.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>4430</offset><text>Patient characteristics</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left"&gt;No&lt;/td&gt;&lt;td align="center"&gt;Sex&lt;/td&gt;&lt;td align="center"&gt;Age&lt;/td&gt;&lt;td align="left"&gt;Diagnosis&lt;/td&gt;&lt;td align="center"&gt;APACHE II&lt;/td&gt;&lt;td align="left"&gt;Medications&lt;/td&gt;&lt;td align="center"&gt;MV&lt;/td&gt;&lt;td align="center"&gt;Outcome&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;1&lt;/td&gt;&lt;td align="center"&gt;F&lt;/td&gt;&lt;td align="center"&gt;58&lt;/td&gt;&lt;td align="left"&gt;SBH&lt;/td&gt;&lt;td align="center"&gt;22&lt;/td&gt;&lt;td align="left"&gt;Midazolam&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;2&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;54&lt;/td&gt;&lt;td align="left"&gt;ICH&lt;/td&gt;&lt;td align="center"&gt;20&lt;/td&gt;&lt;td align="left"&gt;&#8212;&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;D&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;3&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;54&lt;/td&gt;&lt;td align="left"&gt;COPD&lt;/td&gt;&lt;td align="center"&gt;28&lt;/td&gt;&lt;td align="left"&gt;Midazolam&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;D&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;4&lt;/td&gt;&lt;td align="center"&gt;F&lt;/td&gt;&lt;td align="center"&gt;70&lt;/td&gt;&lt;td align="left"&gt;COPD&lt;/td&gt;&lt;td align="center"&gt;30&lt;/td&gt;&lt;td align="left"&gt;Propofol&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;5&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;48&lt;/td&gt;&lt;td align="left"&gt;Head injury&lt;/td&gt;&lt;td align="center"&gt;24&lt;/td&gt;&lt;td align="left"&gt;Fentanyl, Midazolam&lt;/td&gt;&lt;td align="center"&gt;10&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;6&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;19&lt;/td&gt;&lt;td align="left"&gt;GBS&lt;/td&gt;&lt;td align="center"&gt;14&lt;/td&gt;&lt;td align="left"&gt;Fentanyl&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;7&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;40&lt;/td&gt;&lt;td align="left"&gt;Head injury&lt;/td&gt;&lt;td align="center"&gt;29&lt;/td&gt;&lt;td align="left"&gt;Fentanyl, Midazolam&lt;/td&gt;&lt;td align="center"&gt;6&lt;/td&gt;&lt;td align="center"&gt;D&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;8&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;67&lt;/td&gt;&lt;td align="left"&gt;Head injury&lt;/td&gt;&lt;td align="center"&gt;28&lt;/td&gt;&lt;td align="left"&gt;Fentanyl, Midazolam&lt;/td&gt;&lt;td align="center"&gt;7&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;9&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;76&lt;/td&gt;&lt;td align="left"&gt;ICH&lt;/td&gt;&lt;td align="center"&gt;28&lt;/td&gt;&lt;td align="left"&gt;Midazolam&lt;/td&gt;&lt;td align="center"&gt;6&lt;/td&gt;&lt;td align="center"&gt;D&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;10&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;41&lt;/td&gt;&lt;td align="left"&gt;Drug overdose&lt;/td&gt;&lt;td align="center"&gt;12&lt;/td&gt;&lt;td align="left"&gt;&#8212;&lt;/td&gt;&lt;td align="center"&gt;4&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;11&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;74&lt;/td&gt;&lt;td align="left"&gt;ICH&lt;/td&gt;&lt;td align="center"&gt;25&lt;/td&gt;&lt;td align="left"&gt;Midazolam, Fentanyl&lt;/td&gt;&lt;td align="center"&gt;4&lt;/td&gt;&lt;td align="center"&gt;D&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;12&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;74&lt;/td&gt;&lt;td align="left"&gt;Cardiac failure&lt;/td&gt;&lt;td align="center"&gt;27&lt;/td&gt;&lt;td align="left"&gt;Lorazepam&lt;/td&gt;&lt;td align="center"&gt;4&lt;/td&gt;&lt;td align="center"&gt;D&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;13&lt;/td&gt;&lt;td align="center"&gt;F&lt;/td&gt;&lt;td align="center"&gt;64&lt;/td&gt;&lt;td align="left"&gt;ICH&lt;/td&gt;&lt;td align="center"&gt;25&lt;/td&gt;&lt;td align="left"&gt;Midazolam&lt;/td&gt;&lt;td align="center"&gt;6&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;14&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;25&lt;/td&gt;&lt;td align="left"&gt;Head injury&lt;/td&gt;&lt;td align="center"&gt;17&lt;/td&gt;&lt;td align="left"&gt;Lorazepam, Fentanyl&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;15&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;26&lt;/td&gt;&lt;td align="left"&gt;Trauma&lt;/td&gt;&lt;td align="center"&gt;22&lt;/td&gt;&lt;td align="left"&gt;Fentanyl&lt;/td&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;16&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;55&lt;/td&gt;&lt;td align="left"&gt;Head injury&lt;/td&gt;&lt;td align="center"&gt;24&lt;/td&gt;&lt;td align="left"&gt;Propofol&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;17&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;62&lt;/td&gt;&lt;td align="left"&gt;ICH&lt;/td&gt;&lt;td align="center"&gt;27&lt;/td&gt;&lt;td align="left"&gt;&#8212;&lt;/td&gt;&lt;td align="center"&gt;6&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;19&lt;/td&gt;&lt;td align="center"&gt;M&lt;/td&gt;&lt;td align="center"&gt;35&lt;/td&gt;&lt;td align="left"&gt;Head injury&lt;/td&gt;&lt;td align="center"&gt;19&lt;/td&gt;&lt;td align="left"&gt;Propofol, Fentanyl&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Mean&lt;/td&gt;&lt;td/&gt;&lt;td align="center"&gt;52&lt;/td&gt;&lt;td/&gt;&lt;td align="center"&gt;23&lt;/td&gt;&lt;td/&gt;&lt;td align="center"&gt;6&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;SD&lt;/td&gt;&lt;td/&gt;&lt;td align="center"&gt;17&lt;/td&gt;&lt;td/&gt;&lt;td align="center"&gt;5&lt;/td&gt;&lt;td/&gt;&lt;td align="center"&gt;1.7&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>4454</offset><text>No	Sex	Age	Diagnosis	APACHE II	Medications	MV	Outcome	 	1	F	58	SBH	22	Midazolam	5	S	 	2	M	54	ICH	20	&#8212;	5	D	 	3	M	54	COPD	28	Midazolam	5	D	 	4	F	70	COPD	30	Propofol	8	S	 	5	M	48	Head injury	24	Fentanyl, Midazolam	10	S	 	6	M	19	GBS	14	Fentanyl	5	S	 	7	M	40	Head injury	29	Fentanyl, Midazolam	6	D	 	8	M	67	Head injury	28	Fentanyl, Midazolam	7	S	 	9	M	76	ICH	28	Midazolam	6	D	 	10	M	41	Drug overdose	12	&#8212;	4	S	 	11	M	74	ICH	25	Midazolam, Fentanyl	4	D	 	12	M	74	Cardiac failure	27	Lorazepam	4	D	 	13	F	64	ICH	25	Midazolam	6	S	 	14	M	25	Head injury	17	Lorazepam, Fentanyl	5	S	 	15	M	26	Trauma	22	Fentanyl	5	S	 	16	M	55	Head injury	24	Propofol	8	S	 	17	M	62	ICH	27	&#8212;	6	S	 	19	M	35	Head injury	19	Propofol, Fentanyl	8	S	 	Mean		52		23		6		 	SD		17		5		1.7		 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>5210</offset><text>M, male; F, female; S, survival; D, death; ICH, intracerebral
				hemorrhage; GBS, Guillain Barr syndrome; SBH, subarachnoid brain hemorrhage;
				COPD, chronic obstructive pulmonary disease; MV, days of mechanical
				ventilation.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>5442</offset><text>Materials and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5464</offset><text>Patients</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5473</offset><text>Eighteen mechanically ventilated patients (15 men and three women, 			 mean age 52.33 &#177; 17.90 years) were included in this study. The protocol was 			 approved by the Medical Ethics Committee of The University Hospital of Ioannina 			 and consent was obtained from the patients' relatives. Patients with 			 gastrectomy, ileus, respiratory infections, sepsis and hemodynamic instability 			 (low blood pressure needing high doses of inotropes, or wide fluctuation of 			 blood pressure over time) were excluded from the study. The demographic data 			 and the underlying clinical conditions of these patients are summarized in 			 Table 1.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6114</offset><text>Protocol</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6123</offset><text>All patients had a 5 mm diameter nasogastric tube in place for 			 enteral nutritional support and received sucralfate 2 g twice daily for stress 			 ulcer prophylaxis. The position of the nasogas-tric tube was radiographically 			 checked before the study. Sedation and all the other medications were kept 			 unchanged throughout the study (Table 1). Nobody was 			 given paralytic agents, antibiotics or inotropes. The enteral nutrition and 			 other medications via nasogastric tube were withheld 8 h before the onset and 			 during the study. The body position of the patients was semirecumbent at a 45 			 degree angle, and they were put in this position at least 8h before the 			 study.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6818</offset><text>All patients were intubated and mechanically ventilated with an 			 assist-control mode. A low level of positive end-expiratory pressure (PEEP) was 			 used (PEEP: 5 &#177; 1.7 cmH2O). The volume, pressure and the leaking 			 of the cuff of the endotracheal tube was checked, before and at the end of 			 every day of the study. The minimal volume and pressure necessary to prevent 			 air leaking around the cuff were used. The study lasted 2 consecutive days for 			 each patient. Eighteen hours before the study, the patients received, at 6 h 			 intervals, a cisapride suspension (Alimix, Janssen Pharmaceutica, Beerse, 			 Belgium; 1 mg/ml) in a dose of 10 mg, or a placebo given as a bolus randomly via 			 nasogastric tube. The next morning, 60 megabecquerels of Tc99m sulfur colloid 			 were carefully administered via the tube as described by Chernow and colleagues. Bronchial secretions were taken at zero time 			 (baseline radioactivity) and then once an hour for 5 consecutive h. The 			 secretions were taken in a sterile container by bronchial suction. The suction 			 catheter was placed at the level of the carina. The distance of the carina from 			 the tip of the endotracheal tube was measured on a chest X-ray. Just after the 			 end of this procedure, patients who had previously received cisapride were 			 given placebo and vice versa. On the second day, the procedure was repeated in 			 the same way. Blood samples were taken from the first five patients in the 			 study, before and 5 h after isotope instillation and checked for radioactivity. 			 Just before starting the procedure, bronchial secretion, oropharyngeal and 			 gastric samples were taken for microbiological cultures. A gentle suction of 			 gastric content was performed just before the administration of the 			 isotope.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8631</offset><text>Measurements</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8644</offset><text>The activity of Tc99m was measured, using a gamma counter (Gamma 			 Counting system, Crystal TM II, 5400 Series, Packard Instrumental Company), in 			 a standard amount (1 ml) of bronchial secretions. The amount of radioactivity is 			 expressed as counts per min (cpm) after correction for decay according to the 			 equation of radioactive decay law:</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8998</offset><text>N = N0.e-&#955;t</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9015</offset><text>where N0 is the number of parent nuclei present at t = 0,N 			 is the number remaining nuclei at time t, &#955; is a constant of 			 proportionality, called the decay constant, which is different for different 			 isotopes and e is the base of natural logarithm.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9278</offset><text>During the procedure, monitoring was performed with a two-lead 			 electrocardiogram (ECG) and a 12-lead ECG was performed before and soon after 			 the end of every procedure.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9455</offset><text>Statistics</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9466</offset><text>The differences between groups were tested for significance by 			 analysis of variance (ANOVA) test for repeated measures. Results are expressed 			 as mean&#177; SD. A P value less than 0.05 was considered 			 significant.</text></passage><passage><infon key="file">cc-3-1-039-1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>9687</offset><text>The radioactivity of bronchial secretions over time. The values at
				zero time represent the baseline radioactivity. Asterisk (*) denotes
				statistical significance between cisapride and placebo.</text></passage><passage><infon key="file">cc-3-1-039-2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>9887</offset><text>The cumulative radioactivity of bronchial secretions with and
				without cisapride.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>9972</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>9980</offset><text>Sixteen out of 18 patients (88%) demonstrated an increased 		  radioactivity in bronchial secretions and it increased over time both in 		  patients receiving cisapride or placebo. When patients received cisapride, the 		  radioactivity increased from 120 &#177; 18 cpm (baseline radioactivity at zero 		  time) to 1930 &#177; 1340 cpm at the fifth hour (P &lt; 0.05). When 		  patients received a placebo the radioactivity increased from 115 &#177; 22 cpm 		  (baseline radioactivity at the zero time) to 6825 &#177; 5100 cpm 5 h later 		  (P &lt; 0.01). There was no significant difference in baseline 		  radioactivity of bronchial secretions whether the patients were given 		  cisa-pride or placebo. The change in radioactivity of bronchial secretions over 		  time is demonstrated in Fig 1. The difference in 		  radioactivity during cisapride and placebo administration became statistically 		  significant after the third hour (P &lt; 0.05). The cumulative 		  bronchial secretion radioactivity obtained when patients received cisapride was 		  significantly lower than when patients received a placebo (7540 &#177; 5330 and 		  21965 &#177; 16080cpm, respectively; P &lt; 0.05; Fig 2).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11139</offset><text>The microbiological cultures showed that 10 patients had identical 		  microorganisms colonizing the stomach, oropharyngeal area and bronchus. Five 		  patients had the same microorganisms only in the oropharyngeal content and 		  bronchial secretion, and different ones in the gastric content. Three patients 		  had different microorganisms in stomach, oropharynx and bronchus. Two of the 		  studied patients developed VAP during their stay in ICU; both patients had the 		  stomach, oropharynx and bronchus colonized with the causative bacteria of VAP, 		  which were detected by quantitative cultures of protected brush specimens.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11775</offset><text>There was no significant difference in cuff pressure between 		  measurements before and at the end of the study.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11889</offset><text>There was no difference in the blood radioactivity before and 5 h after 		  isotope administration, as it was the same as the background radioactivity.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12041</offset><text>No side effects of cisapride were observed during this study. No 		  cardiac arrhythmia or QT interval prolongation was noted.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>12168</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>12179</offset><text>This study demonstrates that cisapride significantly reduced the 		  pulmonary aspiration of gastric contents in mechanically ventilated patients 		  although the conventional protective methods, such as semirecumbent position 		  and regular checking of cuff leaking, even with cisapride administration are 		  not sufficient to prevent gastric content aspiration completely.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>12556</offset><text>In critically ill patients receiving mechanical ventilation 		  gastrointestinal motility is often impaired. The precise mechanism leading to this gastroparesis is 		  still unknown. Medications such as opiates and dopamine, hyperglycemia or increased intracranial pressure have all been shown to depress the antral motor activity 		  in experimental or clinical conditions. This situation favors not only 		  gastroesophageal reflux but also duo-denogastric reflux, thereby promoting the 		  colonization of the stomach with gastric Gram negative pathogens. Enteral nutrition in patients 		  with inadequate gastric emptying can increase the risk of aspiration, and 		  expand the size of the gastric bacterial reservoir by increasing the gastric 		  volume and the pH. Today most investigators agree that gastric colonization 		  with potentially pathogenic microorganisms is important in the pathogenesis of 		  VAP. Moreover, nasogastric tubes themselves probably impair 		  the function of the lower esophageal sphincter thereby promoting aspiration. In 		  addition, the supine position of patients promotes aspiration and the 		  semirecum-bent position helps minimize the aspiration of gastric contents to 		  lower airways.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>13789</offset><text>Our results showed that aspiration in mechanically ventilated patients 		  occurs even when they are kept in a semire-cumbent position. The administration 		  of cisapride significantly decreases aspiration in these patients. A properly 		  inflated cuff was insufficient to prevent aspiration to lower airways. The 		  incidence of gastric content aspiration in our group of patients was very high. 		  One explanation could be the high percentage of neurological diseases, which 		  are included in our patient population, because severe head injury has been 		  associated with impaired gastric emptying. Another 		  cause of the high incidence of aspiration could be the sedation received by the 		  majority of the patients. There is no clear explanation for the absence of 		  gastric content aspiration in two patients. It is noteworthy, though, that one 		  of them did not receive sedation and the other was given low-dose (5mg/h) 		  mida-zolam. Both survived, and their age, APACHE II score and the days of 		  mechanical ventilation at the day of the study were equivalent to those of the 		  other patients.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>14910</offset><text>These findings are in agreement with other investigators who found 		  that cisapride prevents the morphine-induced delay in gastric emptying. It also significantly accelerates gastric emptying both 		  in patients with gastroesophageal reflux disease and in patients with delayed 		  gastric emptying caused by idiopathic or postsurgical reasons. It has also been suggested that cisapride can minimize 		  the risk of aspiration pneumonia in patients with long-term enteral feeding. In critically ill patients with gastric dilatation 		  and functional gastric paralysis the administration of cisapride showed a 		  clinical benefit. 		  Moreover, cisapride increases the lower esophageal sphincter pressure in normal 		  volunteers and in patients with reflux disease. The 		  velocity of transit in the esophagus remains unchanged with cisapride, but an 		  increase in distal peristalsis is noted.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>15812</offset><text>Oral cisapride usually has few side effects. Nevertheless, cardiac 		  arrhythmias, especially torsade de pointes, and prolonged QT intervals with a 		  potentially fatal outcome have been described in patients with concomitant use 		  of medication that is metabolized by the cytochrome P-450 3a4 isoenzyme, eg 		  imidazole antibiotics or macrolides. Cisapride 		  should be administered with caution in patients who are on any medication known 		  to prolong QT interval and in those with renal insufficiency, a history of 		  arrhythmia or cardiac disease. None of our patients received any of the above 		  medications and, possibly for this reason, no side effects were noted during 		  the period of cisapride administration.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>16545</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>16556</offset><text>In summary, we found that cisapride reduces the risk of gastric contents aspiration in intubated and mechanically ventilated patients who are kept in a semirecumbent position. However, our findings suggest that conventional protective measures such as semicircumstance testing and yearly check-up of cigarette leaking during hand placement do not suffice to prevent gastrial contents from asping in this manner. Further studies are needed to determine whether this drug actually prevents ventilator-associated pneumonia, bronchitis or  asthma attacks.</text></passage><passage><infon key="fpage">44S</infon><infon key="lpage">53S</infon><infon key="name_0">surname:Graven;given-names:DE</infon><infon key="name_1">surname:Steger;given-names:KA</infon><infon key="name_2">surname:Barber;given-names:TW</infon><infon key="pub-id_pmid">1928191</infon><infon key="section_type">REF</infon><infon key="source">Am J Med</infon><infon key="type">ref</infon><infon key="volume">91 (suppl 3B)</infon><infon key="year">1991</infon><offset>17141</offset><text>Preventing nosocomial pneumonia: state of the art and perspectives 			 for the 1990s.</text></passage><passage><infon key="fpage">580</infon><infon key="lpage">599</infon><infon key="name_0">surname:Graven;given-names:DE</infon><infon key="name_1">surname:Steger;given-names:KA</infon><infon key="name_2">surname:Duncan;given-names:RA</infon><infon key="section_type">REF</infon><infon key="source">Wenzel RP (editor).</infon><infon key="type">ref</infon><infon key="year">Baltimore: Williams and Wilkins;
			 Prevention and control of nosocomial infections. 1993</infon><offset>17227</offset><text>Prevention and control of nosocomial pneumonia.</text></passage><passage><infon key="fpage">441</infon><infon key="lpage">447</infon><infon key="name_0">surname:Dive;given-names:A</infon><infon key="name_1">surname:Moulart;given-names:M</infon><infon key="name_2">surname:Jonard;given-names:PH</infon><infon key="pub-id_pmid">8124995</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">1994</infon><offset>17275</offset><text>Gastroduodenal motility in mechanically ventilated critically ill 			 patients: a manometric study.</text></passage><passage><infon key="fpage">1339</infon><infon key="lpage">1344</infon><infon key="name_0">surname:Heyland;given-names:DK</infon><infon key="name_1">surname:Toudas;given-names:G</infon><infon key="name_2">surname:King;given-names:D</infon><infon key="name_3">surname:Cook;given-names:CJ</infon><infon key="section_type">REF</infon><infon key="source">Int Care Med </infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">1996</infon><offset>17375</offset><text>Impaired gastric emptying in mechanically ventilated critically ill 			 patients.</text></passage><passage><infon key="fpage">353</infon><infon key="lpage">356</infon><infon key="name_0">surname:Jacobs;given-names:S</infon><infon key="name_1">surname:Chang;given-names:RW</infon><infon key="name_2">surname:Lee;given-names:B</infon><infon key="name_3">surname:Bartelett;given-names:FW</infon><infon key="section_type">REF</infon><infon key="source">Parenteral Nutrition</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">1990</infon><offset>17457</offset><text>Continuous enteral feeding: a major cause of pneumonia among 			 ventilated intensive care unit patients.</text></passage><passage><infon key="fpage">1711</infon><infon key="lpage">1725</infon><infon key="section_type">REF</infon><infon key="source">Am J Respir Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">153</infon><infon key="year">1995</infon><offset>17563</offset><text>Hospital acquired pneumonia in adults : diagnosis, assessment of 			 severity, initial antimicrobial therapy and preventative strategies. A 			 Consensus Statement of ATS.</text></passage><passage><infon key="fpage">540</infon><infon key="lpage">543</infon><infon key="name_0">surname:Torres;given-names:AJ</infon><infon key="name_1">surname:Serra Batlles Ros;given-names:E</infon><infon key="name_2">surname:Piera;given-names:C</infon><infon key="name_3">surname:Puing de la Belacasa Cobos;given-names: A</infon><infon key="name_4">surname:Lomena;given-names:F</infon><infon key="name_5">surname:Rodriguez Roisin;given-names:R</infon><infon key="pub-id_pmid">1543307</infon><infon key="section_type">REF</infon><infon key="source">Ann Intern Med</infon><infon key="type">ref</infon><infon key="volume">116</infon><infon key="year">1992</infon><offset>17735</offset><text>Pulmonary aspiration of gastric contents in patients receiving 			 mechanical ventilation: the effect of body position.</text></passage><passage><infon key="fpage">1387</infon><infon key="lpage">1390</infon><infon key="name_0">surname:Orozco Levi;given-names:M</infon><infon key="name_1">surname:Torres;given-names:A</infon><infon key="name_2">surname:Ferrer;given-names:M</infon><infon key="pub-id_pmid">7551400</infon><infon key="section_type">REF</infon><infon key="source">Am J Respir Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">152</infon><infon key="year">1995</infon><offset>17855</offset><text>Semirecumbent position protects from pulmonary aspiration but not 			 from gastroesophageal reflux in mechanically ventilated patients.</text></passage><passage><infon key="fpage">1356</infon><infon key="lpage">1362</infon><infon key="name_0">surname:Dive;given-names:A</infon><infon key="name_1">surname:Miesse;given-names:C</infon><infon key="name_2">surname:Galanti;given-names:L</infon><infon key="pub-id_pmid">7634805</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">1995</infon><offset>17991</offset><text>Effect of erythromycin on gastric motility in mechanically 			 ventilated critically ill patients: a double-blind, randomized, 			 placebo-controlled study. </text></passage><passage><infon key="fpage">652</infon><infon key="lpage">681</infon><infon key="name_0">surname:McGallum;given-names:RW</infon><infon key="name_1">surname:Prakash;given-names:C</infon><infon key="name_2">surname:Campoli Richards;given-names:DM</infon><infon key="pub-id_pmid">3065057</infon><infon key="section_type">REF</infon><infon key="source">Drugs</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">1988</infon><offset>18149</offset><text>Cisapride. A preliminary review of its pharmacodynamic and 			 pharmacokinetic properties, and therapeutic use as a prokinetik agent in 			 gastrointestinal motility disorders.</text></passage><passage><infon key="fpage">839</infon><infon key="lpage">844</infon><infon key="name_0">surname:Chernow;given-names:B</infon><infon key="name_1">surname:Johnson;given-names:LF</infon><infon key="name_2">surname:Janowitz;given-names:WR</infon><infon key="name_3">surname:Castell;given-names:DO</infon><infon key="pub-id_pmid">520103</infon><infon key="section_type">REF</infon><infon key="source">Digest Dis Sci</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">1979</infon><offset>18326</offset><text>Pulmonary aspiration as a consequence of gastroesophageal reflux: a 			 diagnostic approach.</text></passage><passage><infon key="fpage">980</infon><infon key="name_0">surname:Giacoli;given-names:D</infon><infon key="section_type">REF</infon><infon key="source">Physics for Scientist and Engineers</infon><infon key="type">ref</infon><infon key="year">Prentice Hall,Second
			 edition.International Edition. 1989</infon><offset>18419</offset></passage><passage><infon key="fpage">509</infon><infon key="lpage">513</infon><infon key="name_0">surname:Nimmo;given-names:WS</infon><infon key="name_1">surname:Heading;given-names:RC</infon><infon key="name_2">surname:Wilson;given-names:J</infon><infon key="name_3">surname:Tothill;given-names:P</infon><infon key="name_4">surname:Prescott;given-names:LF</infon><infon key="pub-id_pmid">9953</infon><infon key="section_type">REF</infon><infon key="source">Br J Clin Pharmacol</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">1975</infon><offset>18420</offset><text>Inhibition of gastric emptying and drug absorption by narcotic 			 analgesics.</text></passage><passage><infon key="fpage">243</infon><infon key="lpage">245</infon><infon key="name_0">surname:Frost;given-names:P</infon><infon key="name_1">surname:Edwards;given-names:N</infon><infon key="name_2">surname:Bihari;given-names:D</infon><infon key="pub-id_pmid">9083223</infon><infon key="section_type">REF</infon><infon key="source">Intensive Care Med</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">1997</infon><offset>18499</offset><text>Gastric emptying in the critically ill - the way forward?</text></passage><passage><infon key="fpage">739</infon><infon key="lpage">744</infon><infon key="name_0">surname:Barnett;given-names:JL</infon><infon key="name_1">surname:Owyang;given-names:CH</infon><infon key="pub-id_pmid">3338642</infon><infon key="section_type">REF</infon><infon key="source">Gastroenterology </infon><infon key="type">ref</infon><infon key="volume">94</infon><infon key="year">1988</infon><offset>18557</offset><text>Serum glucose concentration as a modulator of interdigestive gastric 			 motility.</text></passage><passage><infon key="fpage">60</infon><infon key="lpage">65</infon><infon key="name_0">surname:Matthews;given-names:DE</infon><infon key="name_1">surname:Heimanshon;given-names:DA</infon><infon key="name_2">surname:Papaila;given-names:JG</infon><infon key="pub-id_pmid">3392994</infon><infon key="section_type">REF</infon><infon key="source">J Surg Res</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">1988</infon><offset>18640</offset><text>The effect of increased intracranial pressure on gastric 			 motility.</text></passage><passage><infon key="fpage">911</infon><infon key="lpage">913</infon><infon key="name_0">surname:Inglis;given-names:TJ</infon><infon key="name_1">surname:Sproat;given-names:L</infon><infon key="name_2">surname:Sherratt;given-names:LJ</infon><infon key="name_3">surname:Gibson;given-names:JS</infon><infon key="name_4">surname:Hawkey;given-names:PM</infon><infon key="pub-id_pmid">8096263</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">341</infon><infon key="year">1993</infon><offset>18711</offset><text>Gastroduodenal dysfunction and bacterial colonization of ventilated 			 lung.</text></passage><passage><infon key="fpage">968</infon><infon key="lpage">969</infon><infon key="name_0">surname:Atherton;given-names:ST</infon><infon key="name_1">surname:White;given-names:ST</infon><infon key="pub-id_pmid">81991</infon><infon key="section_type">REF</infon><infon key="source">Lancet </infon><infon key="type">ref</infon><infon key="volume">ii</infon><infon key="year">1978</infon><offset>18789</offset><text>Stomach as a source of bacteria colonising respiratory tract during 			 artificial ventilation.</text></passage><passage><infon key="fpage">187</infon><infon key="lpage">193</infon><infon key="name_0">surname:Heyland;given-names:D</infon><infon key="name_1">surname:Mandell;given-names:LA</infon><infon key="pub-id_pmid">1729067</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">1992</infon><offset>18885</offset><text>Gastric colonization by Gram negative bacilli and nosocomial 			 pneumonia in the intensive care unit patient: evidence of causation.</text></passage><passage><infon key="fpage">352</infon><infon key="lpage">357</infon><infon key="name_0">surname:Torres;given-names:A</infon><infon key="name_1">surname:El-Ebiary;given-names:M</infon><infon key="name_2">surname:Gonzalez;given-names:J</infon><infon key="name_3">surname:Ferrer;given-names:M</infon><infon key="pub-id_pmid">8342898</infon><infon key="section_type">REF</infon><infon key="source">Am Rev Respir Dis</infon><infon key="type">ref</infon><infon key="volume">148</infon><infon key="year">1993</infon><offset>19019</offset><text>Gastric and pharyngeal flora in nosocomial pneumonia acquired during 			 mechanical ventilation.</text></passage><passage><infon key="fpage">536</infon><infon key="lpage">539</infon><infon key="name_0">surname:Rowbotham;given-names:DJ</infon><infon key="name_1">surname:Nimmo;given-names:WS</infon><infon key="pub-id_pmid">3580233</infon><infon key="section_type">REF</infon><infon key="source">Br J Anaesth</infon><infon key="type">ref</infon><infon key="volume">59</infon><infon key="year">1987</infon><offset>19116</offset><text>Effects of cisapride on morphine induced delay in gastric 			 emptying.</text></passage><passage><infon key="fpage">811</infon><infon key="lpage">816</infon><infon key="name_0">surname:Richards;given-names:RD</infon><infon key="name_1">surname:Valenzuela;given-names:GA</infon><infon key="name_2">surname:Davenport;given-names:KG</infon><infon key="pub-id_pmid">8482178</infon><infon key="section_type">REF</infon><infon key="source">Dig Dis Sci</infon><infon key="type">ref</infon><infon key="volume">38</infon><infon key="year">1993</infon><offset>19188</offset><text>Objective and subjective results of randomized double bind, placebo 			 controlled trial using cisapride to treat gastroparesis.</text></passage><passage><infon key="fpage">188</infon><infon key="lpage">190</infon><infon key="name_0">surname:Sartori;given-names:S</infon><infon key="name_1">surname:Trevisani</infon><infon key="name_2">surname:Tassinari;given-names:D</infon><infon key="section_type">REF</infon><infon key="source">Supp Care Cancer</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">1994</infon><offset>19317</offset><text>Prevention of aspiration pneumonia during long-term feeding by 			 percutaneous endoscopic gastrostomy: may cisapride play a role. An open pilot 			 study.</text></passage><passage><infon key="fpage">508</infon><infon key="lpage">509</infon><infon key="name_0">surname:Lauwers;given-names:LF</infon><infon key="section_type">REF</infon><infon key="source">Int Care Med </infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">1991</infon><offset>19473</offset><text>Cisapride in intensive care.</text></passage><passage><infon key="fpage">481</infon><infon key="lpage">485</infon><infon key="name_0">surname:Shapen;given-names:H</infon><infon key="name_1">surname:Duinslaeger;given-names:L</infon><infon key="name_2">surname:Diltoer;given-names:M</infon><infon key="name_3">surname:Gillet;given-names:R</infon><infon key="name_4">surname:Bossuyt;given-names:A</infon><infon key="name_5">surname:Huyghens;given-names:LP</infon><infon key="pub-id_pmid">7874898</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">1995</infon><offset>19502</offset><text>Gastric emptying in critically ill intensive care patients is 			 accelerated by adding cisapride to a standard enteral feeding protocol.</text></passage><passage><infon key="fpage">139</infon><infon key="name_0">surname:Gilbert;given-names:RJ</infon><infon key="name_1">surname:Dodds;given-names:WJ</infon><infon key="name_2">surname:Kahrilas;given-names:PJ</infon><infon key="section_type">REF</infon><infon key="source">Digestion</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">1986</infon><offset>19640</offset><text>Double-blinded assessment of the effect of intravenous and oral 			 cisapride on esophageal motor function.</text></passage><passage><infon key="fpage">465S</infon><infon key="name_0">surname:Case;given-names:WG</infon><infon key="name_1">surname:Williams;given-names:NS</infon><infon key="section_type">REF</infon><infon key="source">Dig Dis Sci </infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">1986</infon><offset>19748</offset><text>The effect of cisapride upon lower esophageal sphincter pressure and 			 primary peristalsis.</text></passage><passage><infon key="fpage">290</infon><infon key="lpage">291</infon><infon key="name_0">surname:Wysowski;given-names:DK</infon><infon key="name_1">surname:Bascanyi;given-names:J</infon><infon key="pub-id_pmid">8657260</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">1996</infon><offset>19842</offset><text>Cisapride and fatal arrhythmia. </text></passage></document></collection>